Key Findings:  The data indicate that agonism at CB2 cannabinoid receptors protects against MPTP-induced nigrostriatal degeneration by inhibiting microglial activation/infiltration and suggest that CB2 receptors represent a new therapeutic target to slow the degenerative process occurring in PD.
Type of Study:  Animal Study
Study Result:  Positive
Cannabinoids Studied:  JWH-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids
Phytocannabinoid Source:  Not Applicable